Table of Contents
6.Summary
Introduction and Definition
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a systemic disorder that arises as a complication of CKD. It encompasses a triad of abnormalities:
1.Biochemical abnormalities: Dysregulation of calcium, phosphorus, parathyroid hormone (PTH), and vitamin D metabolism, along with elevated fibroblast growth factor 23 (FGF23).
2.Skeletal abnormalities: A spectrum of bone diseases collectively known as renal osteodystrophy, affecting bone turnover, mineralization, and volume.
3.Extraskeletal calcification: Pathological mineral deposition in soft tissues, particularly the cardiovascular system.
This disorder is not merely a bone disease but a systemic syndrome with significant clinical consequences, including increased risk of fractures, cardiovascular disease, and mortality. The term CKD-MBD was introduced by the Kidney Disease: Improving Global Outcomes (KDIGO) workgroup in 2006 to provide a broader, more encompassing definition than “renal osteodystrophy,” which is now used to describe the bone-specific manifestations of CKD-MBD.
Pathophysiology
The pathophysiology of CKD-MBD is a complex interplay of hormonal and mineral imbalances that begins early in the course of CKD and progresses as kidney function declines.
Secondary Hyperparathyroidism
As the glomerular filtration rate (GFR) falls, the kidneys’ ability to excrete phosphate is impaired, leading to phosphate retention. This is one of the earliest and most critical events in the development of CKD-MBD. The retained phosphate stimulates the parathyroid glands to produce more PTH, a condition known as secondary hyperparathyroidism. This adaptive response aims to increase urinary phosphate excretion and maintain normal serum phosphate levels.
However, as CKD progresses, the kidneys become resistant to the phosphaturic effects of PTH, leading to a vicious cycle of worsening hyperphosphatemia and progressively higher PTH levels. Additionally, reduced production of active vitamin D (calcitriol) due to decreased 1-alpha-hydroxylase activity in the failing kidneys leads to hypocalcemia, which further stimulates PTH secretion.
The FGF23-Klotho Axis
Fibroblast growth factor 23 (FGF23) is a hormone produced by osteocytes and osteoblasts in response to phosphate loading. FGF23 acts on the kidneys to promote phosphate excretion and reduce the production of active vitamin D (calcitriol) by inhibiting the enzyme 1-alpha-hydroxylase. Klotho, a transmembrane protein primarily expressed in the distal renal tubules, is an essential co-receptor for FGF23.
In early CKD, FGF23 levels rise to compensate for phosphate retention, often maintaining normal serum phosphate levels initially. However, as CKD advances, Klotho expression decreases, leading to FGF23 resistance. The persistently high FGF23 levels, while initially compensatory, contribute to the pathophysiology of CKD-MBD by suppressing calcitriol production, which in turn leads to hypocalcemia and further stimulation of PTH secretion. Elevated FGF23 is also independently associated with increased cardiovascular mortality.
Skeletal Abnormalities (Renal Osteodystrophy)
Renal osteodystrophy is the skeletal component of CKD-MBD and is characterized by abnormalities in bone turnover, mineralization, and volume. The classification of renal osteodystrophy is based on bone biopsy findings and is described by the TMV system (Turnover, Mineralization, Volume).
The main types of renal osteodystrophy are:
| Type | Turnover | Mineralization | Characteristics |
|---|---|---|---|
| Osteitis Fibrosa Cystica | High | Normal | Caused by severe secondary hyperparathyroidism. Characterized by increased bone resorption, peritrabecular fibrosis, and the formation of “brown tumors.” Patients present with bone pain, fractures, and skeletal deformities. |
| Adynamic Bone Disease | Low | Normal | The most common form of renal osteodystrophy. Characterized by a profound reduction in bone formation and resorption, leading to a brittle, fracture-prone skeleton. Often associated with over-suppression of PTH or diabetes mellitus. |
| Osteomalacia | Low | Abnormal | Characterized by defective mineralization of bone, leading to an accumulation of unmineralized osteoid. Historically associated with aluminum toxicity (now rare), or severe vitamin D deficiency. Presents with bone pain and muscle weakness. |
| Mixed Uremic Osteodystrophy | Variable | Variable | A combination of features of high-turnover and low-turnover disease. |
Extraskeletal Calcification
Extraskeletal calcification, particularly vascular calcification, is a major contributor to the high cardiovascular morbidity and mortality in patients with CKD. The mechanisms driving vascular calcification are complex and involve a transformation of vascular smooth muscle cells into osteoblast-like cells, a process promoted by hyperphosphatemia, hypercalcemia, and inflammation.
This leads to the deposition of calcium and phosphate in the medial layer of arteries (medial arterial calcification), resulting in:
•Arterial stiffness
•Increased pulse pressure
•Left ventricular hypertrophy
•Impaired coronary perfusion
•Increased risk of cardiovascular events and death
Approximately 80% of dialysis patients have coronary artery calcification, contributing to 40-50% of deaths in this population.
Clinical Presentation
The clinical presentation of CKD-MBD is often subtle and may be asymptomatic in the early stages. As the disorder progresses, patients may develop a range of signs and symptoms related to bone disease and extraskeletal calcification.
Skeletal Manifestations
•Bone pain: A common and often debilitating symptom, particularly in patients with high-turnover or low-turnover bone disease. Often underreported until treatment is initiated.
•Fractures: Patients with CKD-MBD have an increased risk of fractures, which can occur with minimal trauma. Fracture risk is elevated in both high and low turnover bone disease.
•Skeletal deformities: In children, CKD-MBD can lead to growth retardation and skeletal deformities, such as rickets-like changes.
•Proximal muscle weakness: Myopathy can occur, particularly in patients with severe hyperparathyroidism or aluminum toxicity.
Extraskeletal Manifestations
•Cardiovascular disease: The most significant clinical consequence of CKD-MBD. Patients may present with:
•Hypertension
•Left ventricular hypertrophy (LVH)
•Heart failure
•Arrhythmias
•Accelerated atherosclerosis
•Calciphylaxis: A rare but life-threatening condition characterized by ischemic necrosis of the skin and subcutaneous tissues due to calcification of small blood vessels. Presents with painful skin lesions that can progress to ulceration and necrosis. Mortality rate is extremely high (60-80%).
•Pruritus: Uremic pruritus is a common and distressing symptom in patients with advanced CKD, and it may be exacerbated by hyperphosphatemia.
Evaluation and Diagnosis
The evaluation of CKD-MBD involves a combination of laboratory testing, imaging studies, and, in select cases, bone biopsy.
Laboratory Evaluation
Regular monitoring of serum levels of calcium, phosphorus, PTH, and alkaline phosphatase is recommended for all patients with CKD starting in stage 3. The frequency of monitoring depends on the CKD stage and the presence and magnitude of abnormalities.
KDIGO Recommended Monitoring Schedule:
| Parameter | CKD Stage 3 | CKD Stage 4 | CKD Stage 5 (Dialysis) |
|---|---|---|---|
| Calcium, Phosphorus | Every 6-12 months | Every 3-6 months | Every 1-3 months |
| PTH | Baseline | Every 6-12 months | Every 3-6 months |
| Alkaline Phosphatase | Annually | Annually | Annually |
| 25-hydroxyvitamin D | Baseline, then as needed | Baseline, then as needed | Baseline, then as needed |
Additional Laboratory Tests:
•Bone-specific alkaline phosphatase (bsALP): A more specific marker of bone turnover than total alkaline phosphatase.
•FGF23: Not routinely measured clinically, but elevated levels are associated with adverse outcomes.
•Calcium-phosphate product: Calculated as Ca × P; values > 55 mg²/dL² are associated with increased risk of soft tissue calcification.
Imaging
•Skeletal X-rays: May reveal features of renal osteodystrophy, such as:
•Subperiosteal resorption (a hallmark of hyperparathyroidism, best seen in the phalanges)
•Osteosclerosis (increased bone density, “rugger jersey spine”)
•Osteopenia
•Brown tumors (lytic lesions)
•Bone Mineral Density (BMD): DEXA scans can be used to assess fracture risk, but their interpretation in CKD is complex due to the unique bone pathology. KDIGO suggests that BMD testing may be reasonable if results will alter management.
•Vascular Calcification:
•Lateral abdominal radiographs can detect abdominal aortic calcification
•CT scans can quantify coronary artery calcium score
•Echocardiography may reveal valvular calcification
Bone Biopsy
Bone biopsy with double tetracycline labeling is the gold standard for the definitive diagnosis and classification of renal osteodystrophy. It provides information on bone turnover, mineralization, and volume (TMV classification).
However, it is an invasive procedure and is typically reserved for:
•Patients with unexplained fractures
•Persistent bone pain despite treatment
•Inconsistent or unclear laboratory findings
•Suspected aluminum-related bone disease
•Pre-transplant evaluation in select cases
Management and Treatment
The management of CKD-MBD is a critical aspect of care for patients with CKD and aims to normalize mineral metabolism, prevent bone disease, and reduce the risk of cardiovascular complications. Treatment strategies are guided by the KDIGO clinical practice guidelines and are tailored to the individual patient based on their CKD stage and specific biochemical and skeletal abnormalities.
General Principles
1.Early detection and monitoring starting in CKD stage 3
2.Phosphate control is the cornerstone of management
3.Avoid over-suppression of PTH to prevent adynamic bone disease
4.Minimize calcium loading to reduce vascular calcification risk
5.Individualize therapy based on trends, not isolated values
Non-Dialysis CKD Patients (Stages 3-5)
Phosphate Management
Dietary Phosphate Restriction:
•First-line therapy for hyperphosphatemia
•Target: 800-1000 mg/day
•Requires counseling from a renal dietitian
•Focus on limiting processed foods and food additives containing phosphate
•Vegetarian proteins have lower phosphate bioavailability than animal proteins
Phosphate Binders:
If dietary restriction is insufficient, phosphate-binding medications are initiated:
| Type | Examples | Pros | Cons |
|---|---|---|---|
| Non-calcium-based (preferred) | Sevelamer, Lanthanum carbonate | No calcium loading, reduced vascular calcification risk | Expensive, GI side effects |
| Calcium-based | Calcium carbonate, Calcium acetate | Inexpensive, also treats hypocalcemia | Risk of hypercalcemia and vascular calcification |
| Iron-based | Ferric citrate, Sucroferric oxyhydroxide | Also treats anemia, no calcium loading | GI side effects, dark stools |
Key Point: Limit total elemental calcium intake from binders to < 2 g/day to minimize vascular calcification risk.
Calcium and Vitamin D Management
Vitamin D Repletion:
•Correct vitamin D deficiency (25-hydroxyvitamin D < 20 ng/mL) with ergocalciferol or cholecalciferol
•Same dosing as in the general population
•Avoid in patients with hyperphosphatemia or hypercalcemia
Active Vitamin D Analogs:
•Calcitriol (1,25-dihydroxyvitamin D) or alfacalcidol
•Indicated for severe and progressive secondary hyperparathyroidism
•Starting dose: 0.25 μg three times weekly or daily
•Requires careful monitoring of serum calcium and phosphorus to avoid hypercalcemia and hyperphosphatemia
•Use cautiously in patients with serum phosphorus > 4.5 mg/dL
PTH Management
•Primary goal is to control the underlying drivers: hyperphosphatemia and vitamin D deficiency
•Calcimimetics (e.g., cinacalcet) are generally not recommended for patients with non-dialysis CKD due to the risk of hypocalcemia and lack of proven benefit
Dialysis Patients (CKD Stage 5D)
Phosphate Management
•Dietary phosphate restriction and phosphate binders remain the cornerstone
•Dialysis itself provides significant phosphate removal
•Optimize dialysis prescription (longer or more frequent sessions) to enhance phosphate clearance
•Consider nocturnal or extended hemodialysis for better phosphate control
Calcium and Vitamin D Management
•Dialysate calcium concentration can be adjusted (typically 2.5-3.0 mEq/L) to help manage serum calcium levels
•Active vitamin D analogs are commonly used to control secondary hyperparathyroidism
•Newer vitamin D analogs (paricalcitol, doxercalciferol) may have less calcemic effects than calcitriol
PTH Management
Target PTH Levels:
•KDIGO recommends maintaining PTH in the range of 2-9 times the upper normal limit for the assay
•For most assays, this translates to approximately 150-600 pg/mL
•Avoid over-suppression (risk of adynamic bone disease)
Calcimimetics:
•Cinacalcet (oral) and etelcalcetide (intravenous)
•Mechanism: Increase the sensitivity of the calcium-sensing receptor on the parathyroid gland to extracellular calcium
•Effectively lower PTH, calcium, and phosphorus levels
•Recommended for dialysis patients with refractory hyperparathyroidism
•Side effects: Nausea, vomiting, hypocalcemia
•NOT recommended for non-dialysis CKD patients
Parathyroidectomy:
Surgical removal of the parathyroid glands is reserved for patients with severe, refractory hyperparathyroidism who do not respond to medical therapy.
Indications:
•Persistent hypercalcemia or hyperphosphatemia despite medical therapy
•Progressive bone disease with severe bone pain or fractures
•Calciphylaxis unresponsive to medical management
•Very high PTH levels (typically > 800-1000 pg/mL) unresponsive to calcimimetics and vitamin D analogs
Surgical Options:
•Subtotal parathyroidectomy: Removal of 3.5 glands, leaving remnant tissue
•Total parathyroidectomy with autotransplantation: Complete removal with reimplantation of parathyroid tissue in the forearm
Post-operative Considerations:
•Hungry bone syndrome: Severe hypocalcemia and hypophosphatemia due to rapid bone remineralization
•Requires intensive calcium and vitamin D supplementation with close monitoring
•May persist for weeks to months
Summary
CKD-MBD is a systemic disorder of mineral and bone metabolism that is a common complication of chronic kidney disease. It is characterized by:
1.Biochemical abnormalities: Dysregulation of calcium, phosphorus, PTH, vitamin D, and FGF23
2.Renal osteodystrophy: Spectrum of bone diseases affecting turnover, mineralization, and volume
3.Extraskeletal calcification: Particularly vascular calcification driving cardiovascular mortality
Key Pathophysiologic Mechanisms:
•Phosphate retention is the earliest and most critical event
•Secondary hyperparathyroidism develops as an adaptive response
•FGF23-Klotho axis dysregulation contributes to disease progression
•Vascular calcification is an active, cell-mediated process
Clinical Manifestations:
•Often asymptomatic early; systematic screening is essential
•Skeletal: bone pain, fractures, deformities, muscle weakness
•Cardiovascular: hypertension, LVH, heart failure, accelerated atherosclerosis
•Other: calciphylaxis, pruritus
Management Principles:
•Early detection and monitoring starting in CKD stage 3
•Phosphate control through dietary restriction and non-calcium-based binders
•Vitamin D repletion and cautious use of active vitamin D analogs
•PTH management with calcimimetics in dialysis patients
•Parathyroidectomy for refractory cases
•Individualized therapy based on CKD stage and biochemical profile
Cardiovascular Focus:
•CKD-MBD management is not just about bones—it is about preventing cardiovascular death
•Minimize calcium loading to reduce vascular calcification
•Approximately 80% of dialysis patients have coronary artery calcification
Clinical Pearls
1.Think systemic, not just skeletal: CKD-MBD is a systemic disorder with life-threatening cardiovascular consequences. Vascular calcification is the primary driver of mortality.
2.Phosphate is the key: Hyperphosphatemia is the initial and most important driver of secondary hyperparathyroidism. Controlling phosphate through dietary restriction and non-calcium-based binders is the cornerstone of management.
3.Beware of over-suppression: Adynamic bone disease is now the most common form of renal osteodystrophy. Avoid over-suppressing PTH with aggressive therapy. Target PTH levels of 2-9 times the upper normal limit in dialysis patients.
4.FGF23 rises early: FGF23 elevation is one of the earliest biochemical abnormalities in CKD-MBD, often occurring before changes in serum phosphate or PTH. While not routinely measured, it is independently associated with cardiovascular mortality.
5.Minimize calcium loading: Limit total elemental calcium intake from binders to < 2 g/day. Prefer non-calcium-based phosphate binders to reduce the risk of vascular calcification.
6.Vascular calcification is active: It is not a passive deposition of minerals but an active, cell-mediated process involving transformation of vascular smooth muscle cells into osteoblast-like cells.
7.Bone biopsy is the gold standard: While rarely performed, bone biopsy with double tetracycline labeling is the definitive method for diagnosing and classifying renal osteodystrophy. Most treatment decisions are based on non-invasive markers.
8.Calcimimetics are for dialysis patients: Cinacalcet and etelcalcetide are effective for lowering PTH in dialysis patients but are NOT recommended for non-dialysis CKD patients due to the risk of hypocalcemia.
9.Monitor trends, not isolated values: CKD-MBD management should be based on trends in laboratory values over time, not single measurements. Frequency of monitoring increases with CKD severity.
10.Hungry bone syndrome is real: After parathyroidectomy, patients can develop severe hypocalcemia and hypophosphatemia due to rapid bone remineralization. Anticipate this and provide intensive calcium and vitamin D supplementation.
Basic Level (Medical Students/Residents)
Question 1: Which of the following is the earliest and most critical event in the development of CKD-MBD?
a) Hypocalcemia
b) Phosphate retention
c) Vitamin D deficiency
d) Elevated FGF23
Answer: (b) Phosphate retention
Explanation: As GFR declines, the kidneys’ ability to excrete phosphate is impaired, leading to phosphate retention. This is one of the earliest events in CKD-MBD and triggers the cascade of secondary hyperparathyroidism. While FGF23 also rises early, phosphate retention is the primary driver.
Question 2: A patient with CKD stage 5D on hemodialysis has a PTH level of 1200 pg/mL, serum calcium of 10.5 mg/dL, and phosphorus of 6.0 mg/dL. Which of the following is the most likely type of renal osteodystrophy?
a) Adynamic bone disease
b) Osteomalacia
c) Osteitis fibrosa cystica
d) Mixed uremic osteodystrophy
Answer: (c) Osteitis fibrosa cystica
Explanation: The markedly elevated PTH (1200 pg/mL) with hypercalcemia and hyperphosphatemia is characteristic of severe secondary hyperparathyroidism, which causes osteitis fibrosa cystica (high-turnover bone disease). Adynamic bone disease is associated with low or over-suppressed PTH levels.
Question 3: Which of the following medications works by increasing the sensitivity of the calcium-sensing receptor on the parathyroid gland?
a) Calcitriol
b) Sevelamer
c) Cinacalcet
d) Lanthanum carbonate
Answer: (c) Cinacalcet
Explanation: Cinacalcet is a calcimimetic that increases the sensitivity of the calcium-sensing receptor (CaSR) on the parathyroid gland, leading to decreased PTH secretion. Calcitriol is an active vitamin D analog, while sevelamer and lanthanum are phosphate binders.
Question 4: What is the recommended target for dietary phosphate intake in patients with CKD-MBD?
a) 400-600 mg/day
b) 800-1000 mg/day
c) 1200-1500 mg/day
d) 1800-2000 mg/day
Answer: (b) 800-1000 mg/day
Explanation: The recommended target for dietary phosphate restriction in CKD patients is 800-1000 mg/day. This requires counseling from a renal dietitian and often involves limiting processed foods and choosing vegetarian proteins over animal proteins.
Question 5: Which of the following is the most common form of renal osteodystrophy in contemporary practice?
a) Osteitis fibrosa cystica
b) Adynamic bone disease
c) Osteomalacia
d) Mixed uremic osteodystrophy
Answer: (b) Adynamic bone disease
Explanation: Adynamic bone disease is now the most common form of renal osteodystrophy, characterized by low bone turnover. It is often associated with over-suppression of PTH or diabetes mellitus. Osteitis fibrosa cystica (high-turnover disease) was more common in the past but is less frequent now due to better management of secondary hyperparathyroidism.
Advanced Level (Nephrology Fellows/Nephrologists)
Question 6: A 55-year-old woman with CKD stage 4 (eGFR 25 mL/min) has the following labs: calcium 8.5 mg/dL, phosphorus 5.2 mg/dL, PTH 250 pg/mL, 25-hydroxyvitamin D 15 ng/mL. What is the most appropriate initial management?
a) Start cinacalcet
b) Start calcitriol
c) Replete vitamin D with ergocalciferol and initiate a phosphate binder
d) Refer for parathyroidectomy
Answer: (c) Replete vitamin D with ergocalciferol and initiate a phosphate binder
Explanation: This patient has vitamin D deficiency (< 20 ng/mL) and hyperphosphatemia. The first steps are to correct vitamin D deficiency with ergocalciferol or cholecalciferol and control phosphate with dietary restriction and a phosphate binder. Cinacalcet is not recommended in non-dialysis CKD. Calcitriol should be used cautiously and only after correcting hyperphosphatemia. Parathyroidectomy is reserved for refractory cases.
Question 7: Which of the following statements about FGF23 in CKD-MBD is TRUE?
a) FGF23 levels decrease as CKD progresses
b) FGF23 stimulates calcitriol production
c) Klotho expression increases in advanced CKD
d) Elevated FGF23 is independently associated with cardiovascular mortality
Answer: (d) Elevated FGF23 is independently associated with cardiovascular mortality
Explanation: FGF23 levels rise early in CKD to promote phosphate excretion. However, FGF23 suppresses (not stimulates) calcitriol production by inhibiting 1-alpha-hydroxylase. Klotho expression decreases (not increases) in advanced CKD, leading to FGF23 resistance. Elevated FGF23 is independently associated with increased cardiovascular mortality.
Question 8: A dialysis patient develops painful, violaceous skin lesions with central necrosis on the thighs and abdomen. Labs show calcium 10.8 mg/dL, phosphorus 6.5 mg/dL, PTH 850 pg/mL. What is the most likely diagnosis and appropriate management?
a) Cellulitis; treat with antibiotics
b) Calciphylaxis; stop calcium-based phosphate binders and consider sodium thiosulfate
c) Vasculitis; treat with corticosteroids
d) Nephrogenic systemic fibrosis; stop gadolinium exposure
Answer: (b) Calciphylaxis; stop calcium-based phosphate binders and consider sodium thiosulfate
Explanation: The clinical presentation of painful, violaceous skin lesions with necrosis in a dialysis patient with hyperphosphatemia and elevated PTH is highly suggestive of calciphylaxis. This is a life-threatening condition caused by calcification of small blood vessels. Management includes aggressive wound care, stopping calcium-based phosphate binders, optimizing dialysis, and considering sodium thiosulfate. Parathyroidectomy may be needed for refractory hyperparathyroidism.
Question 9: What is the recommended PTH target range for dialysis patients according to KDIGO guidelines?
a) Normal range (10-65 pg/mL)
b) 1-2 times the upper normal limit
c) 2-9 times the upper normal limit
d) > 10 times the upper normal limit
Answer: (c) 2-9 times the upper normal limit
Explanation: KDIGO recommends maintaining PTH in the range of 2-9 times the upper normal limit for the assay in dialysis patients. For most assays, this translates to approximately 150-600 pg/mL. This range balances the need to control secondary hyperparathyroidism while avoiding over-suppression and adynamic bone disease.
Question 10: A patient undergoes subtotal parathyroidectomy for refractory hyperparathyroidism. Two days post-operatively, labs show calcium 6.8 mg/dL, phosphorus 2.1 mg/dL, and the patient develops perioral numbness and muscle cramps. What is the most likely diagnosis?
a) Hypoparathyroidism from surgical complication
b) Hungry bone syndrome
c) Vitamin D deficiency
d) Magnesium deficiency
Answer: (b) Hungry bone syndrome
Explanation: Hungry bone syndrome is a common complication after parathyroidectomy in patients with severe secondary hyperparathyroidism. It is characterized by severe hypocalcemia and hypophosphatemia due to rapid uptake of calcium and phosphate by bone (rapid remineralization). Treatment requires intensive calcium and vitamin D supplementation with close monitoring. This can persist for weeks to months.
References
1.Moe, S., Drüeke, T., Cunningham, J., Goodman, W., Martin, K., Olgaard, K., … & Eknoyan, G. (2006). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 69(11), 1945-1953.
2.Ketteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., … & Leonard, M. B. (2017). Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney International, 92(1), 26-36.
3.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements, 7(1), 1-59.
4.Isakova, T., Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., … & Wolf, M. (2011). Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International, 79(12), 1370-1378.
5.Evenepoel, P., Cunningham, J., Ferrari, S., Haarhaus, M., Javaid, M. K., Lafage-Proust, M. H., … & Vervloet, M. (2021). European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrology Dialysis Transplantation, 36(1), 42-59.
6.Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology, 15(8), 2208-2218.
7.Nigwekar, S. U., Thadhani, R., & Brandenburg, V. M. (2018). Calciphylaxis. New England Journal of Medicine, 378(18), 1704-1714.
8.Sprague, S. M., Ketteler, M., Rastogi, A., Walpen, S., & Spinowitz, B. (2021). Lanthanum carbonate. Drugs, 81(8), 871-890.
Nephrologist’s CKD–MBD Framework
CKD–MBD is a longitudinal syndrome rather than an isolated abnormality in calcium or phosphate. The clinically useful task is to integrate serial phosphate, calcium, intact PTH, alkaline phosphatase, 25-hydroxyvitamin D, kidney function, medications, dietary exposure, dialysis prescription, fracture history, and vascular or valvular calcification. KDIGO recommends interpreting these variables together and responding to trends rather than treating a single laboratory value in isolation.
Assessment by CKD Stage and Clinical Context
| Clinical setting | Core assessment | Specialist interpretation |
|---|---|---|
| CKD G3a–G3b | Calcium, phosphate, PTH, alkaline phosphatase; 25-hydroxyvitamin D when deficiency is suspected | Look for trends, dietary phosphate burden, medication effects, and early secondary hyperparathyroidism; avoid reflex treatment of a modest isolated PTH elevation. |
| CKD G4–G5 not on dialysis | Serial mineral profile, PTH trajectory, alkaline phosphatase, fracture risk, symptoms, and kidney-failure planning | Evaluate modifiable drivers before vitamin D receptor agonists or surgery; consider bone density testing when it will change management. |
| CKD G5D | Pre-dialysis and post-dialysis calcium context, phosphate, PTH, alkaline phosphatase, binder adherence, dialysis dose, and calcimimetic exposure | Use the entire biochemical pattern; avoid aiming for complete PTH normalization and assess for low-turnover disease when PTH is persistently suppressed. |
| Fracture or bone pain | DXA when appropriate, vertebral imaging, calcium/phosphate/PTH/alkaline phosphatase, medication and fall-risk review | Distinguish osteoporosis from renal osteodystrophy; bone biopsy is considered when histology will change treatment selection. |
Phosphate: Exposure, Absorption, and Treatment
Phosphate retention begins before serum phosphate rises. Increased FGF23 and PTH can maintain serum phosphate at the cost of altered bone and cardiovascular signaling. Management should address dietary phosphate burden, phosphate additives, intestinal absorption, nutritional adequacy, dialysis removal, and adherence. In CKD G3a–G5D, phosphate-lowering treatment is generally considered when phosphate is progressively or persistently elevated, with treatment decisions based on serial measurements rather than a single result.
Dietary counseling should distinguish naturally occurring phosphate from highly absorbable additives and should protect protein quality. A nephrologist should review food labels, processed foods, cola beverages, institutional meals, enteral feeds, and the patient’s cultural diet. Excessive dietary restriction can worsen malnutrition and should be avoided.
| Phosphate-lowering strategy | Best-use considerations | Important cautions |
|---|---|---|
| Dietary modification | Reduce phosphate additives while preserving adequate protein and energy | Over-restriction, loss of plant-based foods, malnutrition, and poor adherence. |
| Calcium-based binders | May be used selectively when calcium exposure and calcification risk are acceptable | Cumulative calcium load, hypercalcemia, adynamic bone disease, and vascular calcification; avoid reflexive long-term use. |
| Sevelamer | Useful when calcium load should be minimized; may reduce pill burden if titrated effectively | Gastrointestinal effects, drug-binding interactions, and adherence burden. |
| Iron-based binders | Ferric citrate or sucroferric oxyhydroxide may combine phosphate control with iron exposure | Monitor iron indices, gastrointestinal tolerance, and interaction with other medications. |
| Lanthanum or other non-calcium agents | Alternative when clinically appropriate and available | Cost, pill burden, gastrointestinal effects, and local formulary constraints. |
Parathyroid Hormone and the Bone–Vascular Axis
PTH should be interpreted as a trajectory in relation to calcium, phosphate, alkaline phosphatase, vitamin D status, and kidney function. In non-dialysis CKD, progressively rising or persistently high PTH should prompt correction of hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency before routine use of active vitamin D analogues. Calcitriol and vitamin D receptor agonists are not routinely used to suppress modest PTH elevations in adults with CKD G3a–G5 not on dialysis because of hypercalcemia and hyperphosphatemia risk.
In CKD G5D, PTH-lowering therapy may include a calcimimetic, calcitriol, a vitamin D analogue, or combinations. KDIGO suggests maintaining intact PTH at approximately 2–9 times the upper normal limit for the assay and responding to marked changes within that range. The exact assay, calcium, phosphate, symptoms, bone turnover, and treatment tolerance remain essential to interpretation.
| Biochemical pattern | Likely concern | Management direction |
|---|---|---|
| Rising PTH with high phosphate | Progressive secondary hyperparathyroidism and phosphate burden | Address phosphate intake, binder use, dialysis removal, vitamin D status, and adherence before escalating therapy. |
| High PTH with low or normal calcium | Secondary hyperparathyroidism; possible vitamin D deficiency or phosphate retention | Correct modifiable drivers and assess alkaline phosphatase and clinical context. |
| High PTH with hypercalcemia | Treatment-related calcium/vitamin D load, tertiary hyperparathyroidism, or another cause | Reduce calcium-based binders and active vitamin D exposure when appropriate; investigate persistent hypercalcemia. |
| Persistently low PTH and low alkaline phosphatase | Possible adynamic or low-turnover bone disease | Avoid indiscriminate PTH suppression and excessive calcium exposure; consider bone assessment before antiresorptive treatment. |
Vitamin D, Calcimimetics, and Parathyroidectomy
Correct nutritional vitamin D deficiency using local protocols while monitoring calcium and phosphate. Active vitamin D receptor agonists are reserved for selected patients, particularly those with severe and progressive hyperparathyroidism after modifiable factors have been addressed. Calcimimetics lower PTH and often calcium, but hypocalcemia, gastrointestinal intolerance, and abrupt biochemical shifts require monitoring. Intravenous etelcalcetide or oral cinacalcet may be used in dialysis patients according to local practice and access.
Parathyroidectomy should be considered for severe, progressive, medically refractory hyperparathyroidism, especially when accompanied by bone pain, fractures, pruritus, calciphylaxis risk, or clinically important hypercalcemia/phosphatemia. Preoperative planning should consider hungry bone syndrome, dialysis prescription, vitamin D status, and postoperative calcium and phosphate replacement.
Renal Osteodystrophy, DXA, and Bone Biopsy
Renal osteodystrophy is the histologic component of CKD–MBD and is classified by turnover, mineralization, and volume. The term CKD-associated osteoporosis is used clinically when fracture risk is the main concern, but reduced bone mineral density does not identify turnover state. DXA can predict fracture risk in CKD when results will influence treatment, yet it cannot by itself distinguish high-turnover osteitis fibrosa from adynamic bone disease or osteomalacia.
Bone biopsy remains the reference method for classifying renal osteodystrophy. It is considered when the result will alter therapy, such as before antiresorptive treatment in advanced CKD with unexplained biochemical abnormalities, unexplained bone pain or fractures, suspected osteomalacia, or concern for adynamic bone disease. Treatment should incorporate fall prevention, exercise, protein adequacy, vitamin D status, and individualized osteoporosis therapy rather than relying on a single biochemical target.
Vascular and Valvular Calcification
Vascular calcification is a marker of cardiovascular risk and may influence phosphate and calcium management. Plain radiographs or echocardiography can identify clinically relevant calcification when the result will change risk discussions or treatment intensity. Avoiding hypercalcemia, excessive calcium-based binder exposure, and unnecessary calcitriol is generally more important than pursuing a numerically normal phosphate or PTH value at the expense of safety.
Dialysis-Specific CKD–MBD Management
In dialysis, evaluate phosphate removal, treatment time, access function, dietary intake, binder timing with meals, and adherence. Persistent hyperphosphatemia should not be attributed to diet alone when dialysis dose or access performance is inadequate. PTH trends should be interpreted with calcium, phosphate, alkaline phosphatase, calcimimetic exposure, and the possibility of low-turnover bone disease. A sudden fall in PTH after treatment escalation can be as clinically important as a persistent rise.
Clinical Pearls for Nephrologists
Do not treat PTH as a standalone target. The most useful CKD–MBD decisions are based on serial trends and the direction of calcium, phosphate, PTH, and alkaline phosphatase together. A normal serum phosphate does not exclude early phosphate retention or high FGF23 activity. A fracture in CKD G4–G5D should trigger a structured bone and medication review, not an automatic antiresorptive prescription. Calcium exposure includes binders, dialysate, supplements, vitamin D preparations, and diet.
Clinical Safety Note
This educational chapter does not replace individualized specialist assessment. CKD–MBD therapies can cause hypercalcemia, hypocalcemia, hyperphosphatemia, adynamic bone disease, vascular calcification, gastrointestinal toxicity, and drug interactions. Confirm serial laboratory trends, review the full medication and dialysis prescription, and use local protocols and multidisciplinary input for surgery, calciphylaxis, fractures, and severe biochemical abnormalities.
Self-Assessment Questions
1. A patient with CKD G4 has PTH rising over four measurements, phosphate intermittently high, normal calcium, and low 25-hydroxyvitamin D. What is the best initial approach? Confirm trends, address phosphate exposure and vitamin D deficiency, review medications and dietary adequacy, and reassess before routine active vitamin D therapy.
2. A dialysis patient has persistent PTH above the assay range with hypercalcemia while receiving calcium-based binders and calcitriol. Which principle is most appropriate? Reduce modifiable calcium and vitamin D drivers, consider calcimimetic therapy when appropriate, and interpret PTH with serial calcium, phosphate, alkaline phosphatase, and symptoms.
3. A patient with CKD G5D sustains a fragility fracture and has low PTH and low alkaline phosphatase. Why is an automatic antiresorptive prescription unsafe? The pattern may indicate low-turnover or adynamic bone disease; turnover assessment and specialist review may change the treatment choice.
References
[1] KDIGO. CKD–MBD Clinical Practice Guideline: https://kdigo.org/guidelines/ckd-mbd/
[2] KDIGO CKD–MBD Work Group. 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD–MBD: https://pmc.ncbi.nlm.nih.gov/articles/PMC6340919/
[3] KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of CKD: https://kdigo.org/guidelines/ckd-evaluation-and-management/
[4] Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 CKD–MBD Guideline Update. Kidney International: https://www.kidney-international.org/article/S0085-2538(17)30249-1/fulltext
[5] KDIGO. Diagnosis and Management of Osteoporosis in CKD: https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2017-CKD-MBD-GL.pdf